| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05NCT05387083 | TARS | Phase 2 | Completed | 2024-06-26Actual |
| A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)NCT05392114 | IONS | Phase 3 | Active not recruiting | 2026-12Estimated |
| A Study in Subjects With Retinitis PigmentosaNCT05392179 | ALDX | Phase 2 | Completed | 2023-06-23Actual |
| A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic CoughNCT05392192 | ALDX | Phase 2 | Completed | 2023-04-13Actual |
| Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)NCT05397470 | Fulcrum Therapeutics | Phase 3 | Terminated | 2024-11-19Actual |
| Ibrexafungerp for the Treatment of Complicated Vulvovaginal CandidiasisNCT05399641 | SCYX | Phase 3 | Completed | 2023-05-16Actual |
| A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver FibrosisNCT05402371 | Hepion Pharmaceuticals, Inc. | Phase 2 | Unknown | 2025-05Estimated |
| A Study of CDX-0159 in Patients With Chronic Inducible UrticariaNCT05405660 | Celldex Therapeutics | Phase 2 | Completed | 2024-06-12Actual |
| A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety SymptomsNCT05407064 | Definium Therapeutics US, Inc. | Phase 2 | Completed | 2023-10-06Actual |
| Dazucorilant in Patients With Amyotrophic Lateral SclerosisNCT05407324 | Corcept Therapeutics | Phase 2 | Active not recruiting | 2026-10Estimated |
| Study of ARO-APOC3 in Adults With DyslipidemiaNCT05413135 | Arrowhead Pharmaceuticals | Phase 2 | Completed | 2025-09-22Actual |
| Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary SarcoidosisNCT05415137 | ATYR | Phase 3 | Completed | 2025-06-25Actual |
| Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)NCT05416307 | ETRA | Phase 2, Phase 3 | Recruiting | 2028-03Estimated |
| Pilot Decentralized TrialNCT05419869 | Alto Neuroscience | Phase 2 | Completed | 2023-01-13Actual |
| A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye DiseaseNCT05424549 | ALDX | Phase 2 | Completed | 2022-05-09Actual |
| Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal CancerNCT05425940 | Exelixis | Phase 3 | Active not recruiting | 2026-06-16Actual |
| A Study of Cytisinicline for Vaping Cessation in Adult SmokersNCT05431387 | Achieve Life Sciences | Phase 2 | Completed | 2023-02-28Actual |
| Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic DermatitisNCT05432596 | ACRS | Phase 2 | Completed | 2023-10-26Actual |
| A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial DefectsNCT05436288 | KPRX | Phase 2 | Completed | 2022-12-22Actual |
| Topical SGX302 for Mild-to-Moderate PsoriasisNCT05442190 | Soligenix | Phase 2 | Completed | 2025-10-22Actual |
| A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)NCT05442775 | Cytokinetics | Phase 3 | Terminated | 2023-06-07Actual |
| A Study of ELX-02 in Patients With Alport SyndromeNCT05448755 | ELOX | Phase 2 | Completed | 2023-09-11Actual |
| Berotralstat Treatment in Children With Hereditary AngioedemaNCT05453968 | BioCryst Pharmaceuticals | Phase 3 | Active not recruiting | 2024-09-11Actual |
| Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGDNCT05454956 | TARS | Phase 2 | Completed | 2023-05-18Actual |
| A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung AdenocarcinomaNCT05456256 | LTRN | Phase 2 | Recruiting | 2026-12Estimated |
| A Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With NASH F3NCT05461105 | Hepion Pharmaceuticals, Inc. | Phase 2 | Completed | 2023-04-15Actual |
| SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.NCT05461170 | VIR | Phase 2 | Active not recruiting | 2031-11Estimated |
| Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in AdultsNCT05463068 | Novavax | Phase 3 | Completed | 2022-08-17Actual |
| Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome.NCT05463679 | AYTU | Phase 3 | Suspended | 2025-06Estimated |
| MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and HypertriglyceridemiaNCT05464784 | MediciNova | Phase 2 | Active not recruiting | 2026-12-31Estimated |
Trial details
- Registry ID
- NCT05387083
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05392114
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05392179
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05392192
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05397470
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05399641
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05402371
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05405660
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05407064
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05407324
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05413135
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05415137
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05416307
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT05419869
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05424549
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05425940
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05431387
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05432596
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05436288
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05442190
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05442775
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05448755
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05453968
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05454956
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05456256
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05461105
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05461170
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05463068
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05463679
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05464784
- Phase
- Phase 2
Primary completion marks the end of data collection for the main study measures, not a results publication date.